AU2001276889A1 - Preventing airway mucus production by administration of egf-r antagonists - Google Patents
Preventing airway mucus production by administration of egf-r antagonistsInfo
- Publication number
- AU2001276889A1 AU2001276889A1 AU2001276889A AU7688901A AU2001276889A1 AU 2001276889 A1 AU2001276889 A1 AU 2001276889A1 AU 2001276889 A AU2001276889 A AU 2001276889A AU 7688901 A AU7688901 A AU 7688901A AU 2001276889 A1 AU2001276889 A1 AU 2001276889A1
- Authority
- AU
- Australia
- Prior art keywords
- egf
- antagonists
- administration
- mucus production
- airway mucus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/616,223 US6846799B1 (en) | 1998-08-18 | 2000-07-14 | Preventing airway mucus production by administration of EGF-R antagonists |
US09/616,223 | 2000-07-14 | ||
PCT/US2001/021970 WO2002005842A2 (en) | 2000-07-14 | 2001-07-11 | Preventing airway mucus production by administration of egf-r antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001276889A1 true AU2001276889A1 (en) | 2002-01-30 |
Family
ID=24468521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001276889A Abandoned AU2001276889A1 (en) | 2000-07-14 | 2001-07-11 | Preventing airway mucus production by administration of egf-r antagonists |
Country Status (7)
Country | Link |
---|---|
US (1) | US6846799B1 (en) |
EP (1) | EP1303301B1 (en) |
JP (2) | JP2004503599A (en) |
AU (1) | AU2001276889A1 (en) |
CA (1) | CA2415325C (en) |
MX (1) | MXPA03000253A (en) |
WO (1) | WO2002005842A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7354894B2 (en) * | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US6924285B2 (en) * | 2002-03-30 | 2005-08-02 | Boehringer Ingelheim Pharma Gmbh & Co. | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them |
WO2007040188A1 (en) * | 2005-10-03 | 2007-04-12 | Sankyo Company, Limited | Medicinal composition for inhibiting the excessive formation of goblet cells |
US20070082865A1 (en) * | 2005-10-11 | 2007-04-12 | Washington University | Compositions and methods for treatment of airway hypersecretion |
EP1921070A1 (en) * | 2006-11-10 | 2008-05-14 | Boehringer Ingelheim Pharma GmbH & Co. KG | Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation |
CA2677336A1 (en) * | 2007-02-06 | 2008-08-14 | Boehringer Ingelheim International Gmbh | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof |
BRPI0816142A2 (en) * | 2007-08-24 | 2015-02-18 | Novartis Ag | NRG1 MODULATOR FOR TREATMENT OF RESPIRATORY DISORDERS. |
NZ586582A (en) * | 2008-02-07 | 2012-07-27 | Boehringer Ingelheim Int | Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production |
JP5539351B2 (en) * | 2008-08-08 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cyclohexyloxy-substituted heterocycles, medicaments containing these compounds, and methods for producing them |
EP2475360A1 (en) * | 2009-09-12 | 2012-07-18 | Reckitt Benckiser LLC | Use of guaifenesin for inhibiting mucin secretion |
US9993444B2 (en) | 2011-01-10 | 2018-06-12 | Invion, Inc. | Use of beta-adrenergic inverse agonists for smoking cessation |
JP6996781B1 (en) * | 2020-10-05 | 2022-01-17 | 株式会社常光 | Method for manufacturing response membrane for anion-selective electrode and response membrane for anion-selective electrode |
CN115792229A (en) * | 2022-01-28 | 2023-03-14 | 华中科技大学同济医学院附属同济医院 | Application of tPA in nasal secretion in preparation of nasal polyp and prognosis detection agent thereof |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4310051A1 (en) * | 1992-04-11 | 1993-10-14 | Byk Gulden Lomberg Chem Fab | Treating allergic rhinitis or conjunctivitis - using 3-substd. 6-(substd. phenyl)-pyridazine deriv., also for treating e.g. nasal polyps |
MY119161A (en) | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
JP2000508335A (en) | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | How to treat cancer |
SE9603725D0 (en) * | 1996-10-11 | 1996-10-11 | Astra Ab | New teatment |
AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
WO1999001421A1 (en) | 1997-07-01 | 1999-01-14 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
ATE277895T1 (en) | 1997-07-01 | 2004-10-15 | Warner Lambert Co | 4-BROMINE OR 4-IODINE-PHENYLAMINO-BENZHYDROXAMIC ACID DERIVATIVES AND THEIR USE AS MEK INHIBITORS |
US6335340B1 (en) | 1997-12-19 | 2002-01-01 | Smithkline Beecham Corporation | compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses |
US6037361A (en) | 1998-03-09 | 2000-03-14 | Warner-Lambert Company | Fluorinated butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
WO2000006560A1 (en) | 1998-07-30 | 2000-02-10 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
DE69915634T2 (en) | 1998-07-30 | 2004-08-12 | Warner-Lambert Co. Llc | TRICYCLIC SULPHONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES |
UA59453C2 (en) | 1998-08-12 | 2003-09-15 | Пфайзер Продактс Інк. | HYDROXYPIPECOLATE HYDROXAMIC ACID DERIVATIVES AS matrix metalloproteinase inhibitors |
RS50273B (en) | 1998-08-18 | 2009-07-15 | The Regents Of The Univeristy Of California, | Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs |
US6420415B1 (en) | 1998-09-21 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Thiol compounds, their production and use |
BR0008524A (en) * | 1999-02-27 | 2001-12-18 | Boehringer Ingelheim Pharma | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for their preparation |
DZ3223A1 (en) * | 1999-10-19 | 2001-04-26 | Merck & Co Inc | TYROSINE KINASES INHIBITORS |
-
2000
- 2000-07-14 US US09/616,223 patent/US6846799B1/en not_active Expired - Fee Related
-
2001
- 2001-07-11 EP EP01954661.3A patent/EP1303301B1/en not_active Expired - Lifetime
- 2001-07-11 CA CA2415325A patent/CA2415325C/en not_active Expired - Fee Related
- 2001-07-11 AU AU2001276889A patent/AU2001276889A1/en not_active Abandoned
- 2001-07-11 MX MXPA03000253A patent/MXPA03000253A/en not_active Application Discontinuation
- 2001-07-11 JP JP2002511774A patent/JP2004503599A/en not_active Withdrawn
- 2001-07-11 WO PCT/US2001/021970 patent/WO2002005842A2/en active Application Filing
-
2009
- 2009-11-16 JP JP2009261019A patent/JP2010065053A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2010065053A (en) | 2010-03-25 |
MXPA03000253A (en) | 2005-04-19 |
CA2415325C (en) | 2013-12-10 |
WO2002005842A3 (en) | 2003-01-03 |
JP2004503599A (en) | 2004-02-05 |
EP1303301A2 (en) | 2003-04-23 |
CA2415325A1 (en) | 2002-01-24 |
WO2002005842A2 (en) | 2002-01-24 |
EP1303301B1 (en) | 2014-02-12 |
US6846799B1 (en) | 2005-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL140855A0 (en) | Preventing airway mucus production by administration of egf-r antagonists | |
IS7043A (en) | Administration of chemically transformed insulin into the lungs | |
EP1572262A3 (en) | Method of delivering local anesthesia | |
AU2003284115A1 (en) | Method of delivering local anesthesia | |
AU2001235691A1 (en) | Use of paullone derivatives for making medicines | |
AU2002360949A1 (en) | 17Alpha-ALKYL-17Beta-OXY-ESTRATRIENES AND INTERMEDIATES FOR THE PRODUCTION THEREOF, AND USE OF SAID 17Alpha-ALKYL-17Beta-OXY-ESTRATRIENES FOR PRODUCING MEDICAMENTS AND PHARMACEUTICAL PREPARATIONS | |
AU2001276889A1 (en) | Preventing airway mucus production by administration of egf-r antagonists | |
AU2002316771A1 (en) | Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems | |
AU2001270778A1 (en) | Production, stabilisation and use of reduced forms of pharmaceutical compounds | |
IL152479A0 (en) | Pharmaceutical form of administration for peptides, methods for its production and use | |
WO2001060343A3 (en) | Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid and/or physiologically compatible salts thereof for producing a medicament for treating cancers | |
AU2002336981A1 (en) | Glycoconjugates of sialic acid derivates, methods for their production and use thereof | |
AU2003294762A1 (en) | Film-type preparations for transmucosal administration of nicotine and method for the production thereof | |
WO2001049651A3 (en) | Aminomethyl-phenyl-cyclohexanone derivatives | |
AU2002341555A1 (en) | Levothyroxine pharmaceutical compositions, methods of making and methods of administration | |
AU2001225664A1 (en) | 5-ht3 receptor antagonists for treatment of disorders involving airway constriction | |
GB2362643B (en) | Production of 'green' cement | |
AU2002254930A1 (en) | Novel medicament compositions based on anticholinergic agents and endothelin antagonists | |
AU2002367426A1 (en) | Neurotrophic factor production/secretion accelerator | |
AU2002220099A1 (en) | Laryngeal mask airway | |
AU6106801A (en) | Trans-clitoral administration of therapy | |
AU2001253468A1 (en) | Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production | |
AU2001292305A1 (en) | Airway mucus secretion inhibitors | |
AU2001280460A1 (en) | Pulmonary administration of flint | |
AU2000276980A1 (en) | Production of concrete |